DOTA-LM3 TFA
Based on 2 publication(s) in Google Scholar
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
For research use only. We do not sell to patients.
- Purity: 98.75%
- Formula: C71H94ClF3N16O21S2
- Molecular Weight:1664.18
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DOTA-LM3 TFA
MoreAll Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
RDC Peptide |
177Lu-DOTA-LM3 TFA is tolerated. 177Lu-DOTA-LM3 TFA in the whole body and in the kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1664.18
-
Formula C71H94ClF3N16O21S2
-
Color White to off-white
-
Sequence
DOTA-[p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
H2O : 100 mg/mL (60.09 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. [Content Brief]
[2]. Baum RP, et al. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021 Nov;62(11):1571-1581. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.6009 mL | 3.0045 mL | 6.0090 mL | 15.0224 mL |
| 5 mM | 0.1202 mL | 0.6009 mL | 1.2018 mL | 3.0045 mL | |
| 10 mM | 0.0601 mL | 0.3004 mL | 0.6009 mL | 1.5022 mL | |
| 15 mM | 0.0401 mL | 0.2003 mL | 0.4006 mL | 1.0015 mL | |
| 20 mM | 0.0300 mL | 0.1502 mL | 0.3004 mL | 0.7511 mL | |
| 25 mM | 0.0240 mL | 0.1202 mL | 0.2404 mL | 0.6009 mL | |
| 30 mM | 0.0200 mL | 0.1001 mL | 0.2003 mL | 0.5007 mL | |
| 40 mM | 0.0150 mL | 0.0751 mL | 0.1502 mL | 0.3756 mL | |
| 50 mM | 0.0120 mL | 0.0601 mL | 0.1202 mL | 0.3004 mL | |
| 60 mM | 0.0100 mL | 0.0501 mL | 0.1001 mL | 0.2504 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
DOTA-LM3 TFA Related Classifications
HY-P5126A Related Classifications
Powered by Bioz
- DOTA-LM3
- Radionuclide-Drug Conjugates (RDCs)
- Somatostatin Receptor
- somatostatin receptor
- LM3
- p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2
- sotopically labeled
- 177Lu-DOTA-LM3
- 68 Ga-DOTA-LM3
- biodistribution
- high tumor uptake
- good tumor retention
- safety
- DOTATOC-negative liver metastases
- pancreatic NET
- extensive tumor thrombosis
- Inhibitor
- inhibitor
- inhibit